Stone V E, Clarke J, Lovell J, Steger K A, Hirschhorn L R, Boswell S, Monroe A D, Stein M D, Tyree T J, Mayer K H
Department of Medicine, Memorial Hospital of Rhode Island, Pawtucket 02860, USA.
J Gen Intern Med. 1998 Sep;13(9):586-93. doi: 10.1046/j.1525-1497.1998.00180.x.
To gather qualitative data regarding HIV/AIDS patients' perspectives about HIV-1 protease inhibitors (PIs), and about their experiences taking and adhering to regimens containing PIs.
Six focus groups of persons under care for HIV were conducted between September and November 1996 regarding participants' knowledge, awareness, experiences when taking, and adherence to antiretroviral regimens containing PIs. An identical discussion guide was used to facilitate all six groups. Focus group proceedings were audiotaped, transcribed, coded for themes, and analyzed qualitatively.
HIV/AIDS practices of three teaching hospitals and two community health centers.
PATIENTS/PARTICIPANTS: Fifty-six patients with HIV disease: 28 men and 28 women.
Knowledge and positive impressions of PIs were prevalent among this diverse group of persons with HIV, and did not differ by race/ethnicity or gender. Most knew that these were new, potent medications for treating HIV/AIDS. Networks of persons with HIV and medical providers were the most important information sources. Those taking PIs were aware that adherence to the regimen is important, and most were using special strategies to maximize their own adherence, but expressed considerable frustration about the central role these medication regimens had assumed in their life. A subset who did not believe they would adhere to these regimens had declined treatment with them. Motivating factors for taking and adhering to these complex regimens were improving CD4 counts and viral loads and the patient-provider relationship.
Among those with HIV/AIDS, awareness of PIs and their effectiveness is substantial, owing to the impact of informal networks and medical providers. This early positive "reputation" of PIs may enhance motivation for adherence. Those who are taking PIs invest substantial effort adhering to these complex regimens, but resent the need to make medications the focus of their lives.
收集有关艾滋病病毒/艾滋病(HIV/AIDS)患者对HIV-1蛋白酶抑制剂(PIs)的看法,以及他们服用和坚持含PIs治疗方案的经历的定性数据。
1996年9月至11月间,针对接受HIV治疗的人员进行了6个焦点小组访谈,内容涉及参与者对含PIs的抗逆转录病毒治疗方案的知识、认知、服用经历及依从性。所有6个小组都使用了相同的讨论指南。焦点小组讨论过程进行了录音、转录、主题编码和定性分析。
三家教学医院和两家社区卫生中心的HIV/AIDS诊疗科室。
患者/参与者:56例HIV感染者,男28例,女28例。
在这群多样化的HIV感染者中,对PIs的了解和积极印象普遍存在,且不因种族/民族或性别而有所不同。大多数人知道这些是治疗HIV/AIDS的新型强效药物。HIV感染者网络和医疗服务提供者是最重要的信息来源。服用PIs的人意识到坚持治疗方案很重要,大多数人正在采用特殊策略来最大限度地提高自己的依从性,但对这些药物治疗方案在他们生活中占据的核心地位表示相当沮丧。一部分不相信自己能坚持这些治疗方案的人拒绝了使用它们进行治疗。服用和坚持这些复杂治疗方案的激励因素是提高CD4细胞计数和病毒载量以及患者与医疗服务提供者的关系。
在HIV/AIDS患者中,由于非正式网络和医疗服务提供者的影响,对PIs及其有效性的认知程度较高。PIs这种早期的积极“声誉”可能会增强依从性的动力。服用PIs的人在坚持这些复杂治疗方案上投入了大量精力,但对将药物作为生活焦点的必要性感到不满。